(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
CAMBRIA-2
NCT05952557
 Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
 HOPITAL DE CHICOUTIMI
|
|
Sabrina Côté
418-541-1000 poste 3065
|
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
B-62/CAMBRIA-1
NCT05774951
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Pascale Duchesne
418-541-1000 poste 2840
Sabrina Côté
418-541-1000 poste 3065
|
Étude de phase 3, ouverte, randomisée, comparant le gédatolisib associé au fulvestrant et avec ou sans palbociclib aux traitements standard chez des patientes atteintes d'un cancer du sein avancé HR-positif, HER2-négatif précédemment traitées avec un inhibiteur CDK4/6 en association avec traitement par inhibiteur non stéroïdien de l'aromatase
VIKTORIA-1
NCT05501886
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Mary-Denise Dufour
418-541-1000 poste 2823
|
(EN) Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined With Clinico-Pathological Features
ELISA
NCT04797299
Actif en recrutement
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
|
Caroline Hivon
450-466-5000 poste 2164
|
(EN) An interventional safety and efficacy phase 1b/2, open-label umbrella study to investigate tolerability, pk, and antitumor activity of ARV-471 (PF-07850327), an oral proteolysis targeting chimera, in combination with other anticancer treatments in participants aged 18 years and over with ER+ advanced or metastatic breast cancer, sub-study B (ARV-471 in combination with ribociclib)
TACTIVE-U
NCT05573555
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Alexandra Simard
418-541-1000 poste 3163
|
(EN) An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
MK-2870-010
NCT06312176
Actif en recrutement
|
CISSS DU BAS-SAINT-LAURENT
HOPITAL REGIONAL DE RIMOUSKI
|
|
Isabelle Gagnon
418-724-3000 poste 8029
|
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
CAMBRIA-1
NCT05774951
Actif en recrutement
|
CISSS DES LAURENTIDES
HOPITAL DE SAINT-JEROME
|
|
Yanick Sardin Laframboise
450-431-1020 poste 23429
|
(EN) A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
TROPION-Breast05
NCT06103864
Actif en recrutement
|
SITE GLEN
|
|
Ryan Liu
514-934-1934 poste 34905
|
Essai randomisé portant sur la radiothérapie régionale pour le traitement du cancer du sein avec envahissement ganglionnaire à faible risque avec biomarqueur.
MA.39
NCT03488693
Actif en recrutement
|
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Phase III |
Arielle Langburt
514-340-8222 poste 26801
|
(EN) Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy and With a PathologIc Complete REsponse After Neoadjuvant Chemotherapy
ROSALIE
NCT05866458
Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
|
Gladys El Helou
514-340-8222 poste 26581
Olga Prescornic
514-340-8222 poste 23471
|
Groupe d'étude en oncologie du Québec